Form 4: Ionis Pharmaceuticals Executive Joseph Baroldi Reports Stock Transactions

Executive Vice President and Chief Business Officer of Ionis Pharmaceuticals, Joseph Baroldi, reports acquisition and disposal of company stock and derivative securities.

Summary

• Joseph Baroldi, EVP and Chief Business Officer at Ionis Pharmaceuticals, reported several transactions involving company stock and derivative securities.
• On January 15, 2025, Baroldi acquired 8,787 shares of common stock and 2,460 shares indirectly through his spouse, both related to vesting of Restricted Stock Units.
• On January 16, 2025, Baroldi sold 3,401 shares of common stock at $32.7 per share and his spouse sold 1,029 shares at the same price, to cover tax obligations.
• Baroldi was also granted 22,000 Performance Restricted Stock Units (PRSUs) and 33,000 Restricted Stock Units (RSUs) on January 15, 2025.
• His spouse was granted 3,750 Restricted Stock Units on the same date.
• The PRSUs have a three-year performance period and may vest up to 200% of the target number based on the company's relative total shareholder return compared to a peer group.
• The RSUs vest in four equal annual installments.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions, with no significant positive or negative implications. The vesting of stock units is a positive, but the sale of shares is neutral as it is for tax purposes.

Positives

• The vesting of Restricted Stock Units indicates that performance targets were met, which is a positive sign for the company.
• The grant of new Performance Restricted Stock Units and Restricted Stock Units suggests continued confidence in the company's future performance.

Negatives

• The sale of 3,401 shares by Baroldi and 1,029 shares by his spouse, while for tax purposes, could be perceived negatively by some investors.

Risks

• The vesting of Performance Restricted Stock Units is contingent on the company's relative total shareholder return, which introduces performance risk.
• The actual number of PRSUs that will vest may be anywhere from zero to the maximum amount stated.

Future Outlook

The Performance Restricted Stock Units will vest based on the company's relative total shareholder return over a three-year period, indicating a focus on long-term performance.

Industry Context

This is a routine disclosure of insider transactions, which is common in the pharmaceutical industry where equity compensation is a significant part of executive pay.

Comparison to Industry Standards

• Equity compensation, including RSUs and PRSUs, is a standard practice in the biotech and pharmaceutical industry, used to align executive interests with shareholder value.
• Companies like Biogen, Gilead Sciences, and Amgen also use similar equity-based compensation plans for their executives.
• The vesting schedules and performance metrics for these awards are generally consistent with industry norms, focusing on long-term value creation and shareholder returns.

Stakeholder Impact

• Shareholders may view the vesting of stock units positively, as it indicates the achievement of performance targets.
• The sale of shares by the executive, while for tax purposes, could be perceived negatively by some investors.

Next Steps

• The vesting of the Performance Restricted Stock Units will be determined at the end of the three-year performance period.
• The Restricted Stock Units will vest in four equal annual installments.

Key Dates

Keywords

Ionis Pharmaceuticals, Joseph Baroldi, stock transactions, Restricted Stock Units, Performance Restricted Stock Units, insider trading, equity compensation